- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Colchicine-resistant or intolerant Familial Mediterranean Fever (crFMF)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Canakinumab – March 2026
Solution for injection 150 mg in 1 mL,
Last updated
11 March 2026